US20040043962A1 - Method for enhancing the effectiveness of cancer therapies - Google Patents
Method for enhancing the effectiveness of cancer therapies Download PDFInfo
- Publication number
- US20040043962A1 US20040043962A1 US10/657,383 US65738303A US2004043962A1 US 20040043962 A1 US20040043962 A1 US 20040043962A1 US 65738303 A US65738303 A US 65738303A US 2004043962 A1 US2004043962 A1 US 2004043962A1
- Authority
- US
- United States
- Prior art keywords
- compound
- patient
- administering
- galectin
- modified pectin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- VLFZHMWZMNJMTK-UHFFFAOYSA-N CCC.CCC.CCC.CCC Chemical compound CCC.CCC.CCC.CCC VLFZHMWZMNJMTK-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/732—Pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- This invention relates generally to methods and materials for the treatment of cancer. More specifically, the invention relates to methods and materials for enhancing the effectiveness of cancer therapies.
- Galectins comprise a family of proteins which are expressed by plant and animal cells and which bind ⁇ -galactoside sugars. These proteins can be found on cell surfaces, in cytoplasm, and in extracellular fluids. They have a molecular weight in the general range of 29-34 kD; they have an affinity for ⁇ -galactoside containing materials, and have been found to play a number of important roles in biological processes including cell migration, cell-cell adhesion, angiogenesis, cell fusion and other cell-cell interactions, as well as immune-based reactions and apoptosis. As such, the role of galectins is very strongly tied to cancer and other proliferative diseases. While there are a large number of galectins which manifest the foregoing activities, galectin-3 and galectin-1 have been strongly implicated in connection with cellular processes involving cancers.
- Galectin-3 is a carbohydrate binding protein having a molecular weight of approximately 30,000. It is composed of two distinct structural motifs, an amino-terminal portion containing Gly-X-Y tandem repeats which are characteristic of collagens, and a carboxyl-terminal portion containing a carbohydrate binding site. Galectin-3 is found in almost all tumors, and has a binding affinity for ⁇ -galactoside-containing glyco-conjugates. Galectin-3 is believed to play a role in mediating cell-cell interactions and thereby fostering metastasis. It has been found that cells which have high expressions of galectin-3 are more prone to metastasis and are more resistant to apoptosis induced by chemotherapy or radiation. It has also been reported in the literature that galectin-3 plays a role in promoting angiogenesis.
- Galectin-1 is a highly conserved homodimer of 14-15 kD and is one of the most abundant of the galectins. It binds to laminin which has been found to exert strong regulatory effects on cellular interactions such as adhesion, proliferation, migration and differentiation. In this regard, galectin-1 has been found to strongly influence these processes in various cells. It is believed to be implicated in the secretion of a number of cellular growth factors and interleulcins. Galectin-1 has been found to be expressed at very high levels in many cancer cells and is strongly implicated in metastasis.
- certain therapeutic materials can bind to galectins thereby inactivating them toward interaction with other carbohydrate materials and/or cells.
- treatment of galectin bearing cells with the therapeutic materials of this invention can inhibit the interaction of those cells with other cells and/or biomolecules and thereby inhibit angiogenesis and enhance the efficacy of apoptosis-inducing therapies such as chemotherapy or radiation.
- these materials can inhibit cell-cell interactions and thereby enhance the effectiveness of surgical therapies by inhibiting metastases, which are often initiated by surgical dislodgement of cells.
- the materials of the present invention are generally comprised of natural or synthetic polymers and oligomers. They are very low in toxicity and interact synergistically with heretofore employed cancer therapies so as to increase the effectiveness thereof.
- the dosages of potentially toxic therapies such as chemotherapies and radiation may be reduced.
- the effectiveness of surgical therapies is enhanced by the use of the present invention.
- the methodology of the present invention acts to inhibit the post-surgery metastatic process, use of this invention allows a surgeon to implement more aggressive surgical therapies without being limited by the possibility of precipitating metastatic events.
- the treatment being enhanced may comprise chemotherapy, radiation therapy, surgery and combinations thereof.
- the method of the present invention comprises administering to a patient a therapeutically effective amount of a compound which binds to a galectin. This compound may be administered prior to, after, or concomitant with the other treatment.
- a preferred class of therapeutic materials of the present invention comprises a polymeric backbone having side chains dependent therefrom.
- the side chains are terminated by a galactose or arabinose unit.
- This material may be synthetic, natural, or semi-synthetic.
- the therapeutic compound comprises a substantially demethoxylated polygalacturonic acid backbone which is interrupted with rhamnose residues.
- the materials of the present invention have a molecular weight in excess of 300 dalton.
- One specific group of materials has a molecular weight in the range of 300 to 2,000 daltons.
- a preferred group of materials has a molecular weight in the range of 1-50 kilodalton.
- the therapeutic materials of the present invention may be administered orally, by injection, transdermally, or by topical application, depending upon the specific type of cancer being treated, and the adjunct therapy.
- the present invention recognizes that the effectiveness of conventional cancer therapies such as chemotherapy, surgery and radiation can be enhanced through the use of a therapeutic material which interacts with galectins.
- preferred materials for the practice of the present invention generally comprise molecules which contain an active galectin binding sugar site, but which have somewhat higher molecular weights than simple sugars. Such molecules preferably have a minimum molecular weight of at least 300 daltons, and most typically a minimum molecular weight in the range of 300-2,000 daltons.
- a preferred class of therapeutic materials comprises oligomeric or polymeric species having one or more sugars such as galactose or arabinose pendent therefrom.
- the oligomeric or polymeric backbone may be synthetic or organic. Materials of this type are disclosed in U.S. Pat. No. ______ (EX Ser. No. 09/750,726) the disclosure of which is incorporated herein by reference. Such materials will preferably have a molecular weight in the range of 300-50,000 daltons and one particular material comprises a cellulose backbone with galactose terminated side chains pendent therefrom.
- One group of materials falling within this general class comprises a substantially demethoxylated polygalacturonic acid backbone having rhamnose residues pendent therefrom. It is believed that in materials of this type, the terminal galactose or arabinose units pendent from the backbone bind to galectin proteins. The remaining bulk of the molecule potentiates the compound's action in moderating immune system response; and as discussed hereinabove, the inventors, while not wishing to be bound by speculation, believe that the remaining bulk of the molecule either interacts with remaining portions of the galectin protein and/or prolongs the binding of the sugar portion thereto. Materials of this general type are described by formulas I, II and III hereinbelow, and it is to be understood that yet other variants of this general compound may be prepared and utilized in accord with th e principles of the present invention.
- Pectin is a complex carbohydrate having a highly branched structure comprised of a polygalacturonic backbone with numerous branching side chains dependent therefrom. The branching creates regions which are characterized as being “smooth” and “hairy.” It has been found that pectin can be modified by various chemical, enzymatic or physical treatments to break the molecule into smaller portions having a more linearized, substantially demethoxylated polygalacturonic backbone with pendent side chains of rhamnose residues having decreased branching. This material is known in the art as modified pectin, and its efficacy in treating cancer has been established; although galectin blocker materials of this type have not been used in conjunction with surgery, chemotherapy or radiation.
- U.S. Pat. No. 5,895,784 the disclosure of which is incorporated herein by reference, describes modified pectin materials, techniques for their preparation, and use of the material as a treatment for various cancers.
- the material of the '784 patent is described as being prepared by a pH based modification procedure in which the pectin is put into solution and exposed to a series of programmed changes in pH which results in the breakdown of the molecule to yield therapeutically effective modified pectin.
- the material in the '784 patent is most preferably prepared from citrus pectin; although, it is to be understood that modified pectins may be prepared from pectin starting material obtained from other sources, such as apple pectin and the like.
- Modified pectins of this type generally have molecular weights in the range of 1-50 kilodalton, and a preferred group of such materials has an average molecular weight in the range of 1-15 kilodalton, with a specific group of materials having a molecular weight of about 10 kilodalton.
- modified pectin materials have therapeutic efficacy against a variety of cancers. These materials interact with galectins, including galectin-1 and galectin-3, and in that regard also have efficacy against immune based diseases.
- galectins including galectin-1 and galectin-3, and in that regard also have efficacy against immune based diseases.
- the effect of conventional cancer therapies is enhanced by use of pectin materials and other materials which interact with galectins. These materials may be administered orally; or by intravenous injection; or by injection directly into an affected tissue, as for example by injection into a tumor site. In some instances the materials may be applied topically at the time surgery is carried out. Also, other techniques such as transdermal delivery systems, inhalation, subcutaneous implantation, or the like may be employed.
- Radiation therapy for cancer which includes gamma radiation as well as particle beams, and oncolytic chemotherapeutic agents are cytotoxic, and their effectiveness in treating cancer is based upon the fact that cancerous cells are generally more sensitive to such cytotoxic therapies than are normal cells either because of their rapid metabolism, or because they employ biochemical pathways not employed by normal cells. It is believed that these therapies exert their cytotoxic effects by activating programmed cell death, also referred to as apoptosis. Cells undergo apoptosis when they undergo a critical level of damage. A balance between the activities of apoptotic and anti-apoptotic intracellular signal transduction pathways is important toward a cell's decision of whether to undergo apoptosis or to attempt internal repair. It has been demonstrated that galectins, and specifically galectin-3, are involved in both apoptosis resistance and tumor progression.
- Galectin-3 has been implicated in inhibiting apoptosis in cells treated with oncolytic agents such as cisplatin, genistein and the like. It was found that genistein effectively induces apoptosis, without detectable cell cycle arrest, in BT549 cells, which comprise a human breast epithelial cell line that does not express detectable levels of galectin-3. However, when galectin-3 transfected BT549 cells are treated with genistein, cell cycle arrest at the G(2)/M phase takes place without apoptosis induction (Lin et al. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis.
- galectin-3 is a critical determinant for anchorage-independent cell survival of disseminating cancer cells in the circulation during metastasis. (Kim et al. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells. Cancer Res. 1999 Aug. 15; 59(16):4148-54).
- Galectin-3 has also been shown to protect cells from apoptosis by moderating cell-cell and cell-matrix interaction, and has been shown to be involved in tumor progression and metastasis.
- galectin-3 transfected human breast cancer cells are compared with their parent cell line which do not express galectin-3, it is found that the overexpressing cells: (1) had a significantly enhanced adhesion to laminin, fibronectin and vitronectin exerted both directly and/or via increased expression of specific integrins; the cells also exhibited (2) a remodeling of those cytoskeletal elements associated with cell spreading, i.e.
- microfilaments and (3) enhanced survival upon exposure to different apoptotic stimuli such as cytokine and radiation (Matarrese et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties. Int. J Cancer 2000 Feb. 15; 85(4):545-54).
- apoptotic stimuli such as cytokine and radiation
- galectins The role of galectins in promoting angiogenesis has also been shown. It is known that in order for a primary tumor to grow or metastasize the cell must release chemical information instructing endothelial cells to form blood vessels which nourish and support the tumor cell. Galectins have also proven to be involved in the processes of metastasis and angiogenesis. It is shown that galectin-3 affects chemotaxis and morphology, and stimulates capillary tube formation of IIUV-EC-C in vitro and angiogenesis in vivo. Endothelial cell morphogenesis is a carbohydrate-dependent process which is neutralized by specific sugars and antibodies.
- galectins in general and galectin-3 in particular have been demonstrated to have diverse and very significant effects on the growth and proliferation of cancer cells.
- compounds which block or neutralize the activity of galectins inhibit angiogenesis and promote apoptosis. Therefore, such material will beneficially enhance the effects of oncolytic therapies.
- it has been demonstrated that such materials will strongly inhibit angiogenesis and/or metastasis; therefore, these materials will prevent or minimize metastatic events induced by surgical disruption of a tumor site.
- a galectin binding therapeutic material is administered to a patient, in combination with conventional therapies such as surgery, radiation or chemotherapy.
- the material is most preferably administered prior to the administration of the conventional therapy, so as to allow it sufficient time to interact with and bind to galectins in the tumor or in non-cancerous cells.
- administration of the galectin binding therapeutic material may be continued while the other therapy is being administered and/or thereafter.
- Administration of the galectin binding material may be made in a single dose, or in multiple doses.
- administration of the therapeutic material is commenced at least several days prior to the conventional therapy, while in other instances, administration is begun either immediately before or at the time of the administration of the conventional therapy.
- the carbohydrate material may be advantageously administered both before, during and after the therapy.
Abstract
Description
- This patent application claims priority of U.S. Provisional Patent Application Serial No. 60/299,991 filed Jun. 21, 2001, and entitled “Method for Enhancing the Effectiveness of Cancer Therapies.”
- This invention relates generally to methods and materials for the treatment of cancer. More specifically, the invention relates to methods and materials for enhancing the effectiveness of cancer therapies.
- Conventional treatment for cancers involves the use of chemotherapeutic agents, radiation, and surgery, either alone or in combination. The medical arts have developed a number of treatments based upon the foregoing therapies. The present invention is directed to specific materials which can act to enhance the effectiveness of the foregoing therapies.
- Galectins comprise a family of proteins which are expressed by plant and animal cells and which bind β-galactoside sugars. These proteins can be found on cell surfaces, in cytoplasm, and in extracellular fluids. They have a molecular weight in the general range of 29-34 kD; they have an affinity for β-galactoside containing materials, and have been found to play a number of important roles in biological processes including cell migration, cell-cell adhesion, angiogenesis, cell fusion and other cell-cell interactions, as well as immune-based reactions and apoptosis. As such, the role of galectins is very strongly tied to cancer and other proliferative diseases. While there are a large number of galectins which manifest the foregoing activities, galectin-3 and galectin-1 have been strongly implicated in connection with cellular processes involving cancers.
- Galectin-3 is a carbohydrate binding protein having a molecular weight of approximately 30,000. It is composed of two distinct structural motifs, an amino-terminal portion containing Gly-X-Y tandem repeats which are characteristic of collagens, and a carboxyl-terminal portion containing a carbohydrate binding site. Galectin-3 is found in almost all tumors, and has a binding affinity for β-galactoside-containing glyco-conjugates. Galectin-3 is believed to play a role in mediating cell-cell interactions and thereby fostering metastasis. It has been found that cells which have high expressions of galectin-3 are more prone to metastasis and are more resistant to apoptosis induced by chemotherapy or radiation. It has also been reported in the literature that galectin-3 plays a role in promoting angiogenesis.
- Galectin-1 is a highly conserved homodimer of 14-15 kD and is one of the most abundant of the galectins. It binds to laminin which has been found to exert strong regulatory effects on cellular interactions such as adhesion, proliferation, migration and differentiation. In this regard, galectin-1 has been found to strongly influence these processes in various cells. It is believed to be implicated in the secretion of a number of cellular growth factors and interleulcins. Galectin-1 has been found to be expressed at very high levels in many cancer cells and is strongly implicated in metastasis.
- In accord with the present invention, it has been found that certain therapeutic materials can bind to galectins thereby inactivating them toward interaction with other carbohydrate materials and/or cells. Specifically, it has been found that treatment of galectin bearing cells with the therapeutic materials of this invention can inhibit the interaction of those cells with other cells and/or biomolecules and thereby inhibit angiogenesis and enhance the efficacy of apoptosis-inducing therapies such as chemotherapy or radiation. Furthermore, these materials can inhibit cell-cell interactions and thereby enhance the effectiveness of surgical therapies by inhibiting metastases, which are often initiated by surgical dislodgement of cells.
- As will be explained in detail hereinbelow, the materials of the present invention are generally comprised of natural or synthetic polymers and oligomers. They are very low in toxicity and interact synergistically with heretofore employed cancer therapies so as to increase the effectiveness thereof. Through the use of the present invention, the dosages of potentially toxic therapies such as chemotherapies and radiation may be reduced. Likewise, the effectiveness of surgical therapies is enhanced by the use of the present invention. For example, since the methodology of the present invention acts to inhibit the post-surgery metastatic process, use of this invention allows a surgeon to implement more aggressive surgical therapies without being limited by the possibility of precipitating metastatic events. These and other advantages of the invention will be discussed hereinbelow.
- There is disclosed herein a method for enhancing the efficacy of a therapeutic treatment for cancer in a patient. The treatment being enhanced may comprise chemotherapy, radiation therapy, surgery and combinations thereof. The method of the present invention comprises administering to a patient a therapeutically effective amount of a compound which binds to a galectin. This compound may be administered prior to, after, or concomitant with the other treatment.
- A preferred class of therapeutic materials of the present invention comprises a polymeric backbone having side chains dependent therefrom. The side chains are terminated by a galactose or arabinose unit. This material may be synthetic, natural, or semi-synthetic. In one particular embodiment, the therapeutic compound comprises a substantially demethoxylated polygalacturonic acid backbone which is interrupted with rhamnose residues.
- In general, the materials of the present invention have a molecular weight in excess of 300 dalton. One specific group of materials has a molecular weight in the range of 300 to 2,000 daltons. In those instances where the materials of the present invention are based upon complex carbohydrates such as pectins, a preferred group of materials has a molecular weight in the range of 1-50 kilodalton. The therapeutic materials of the present invention may be administered orally, by injection, transdermally, or by topical application, depending upon the specific type of cancer being treated, and the adjunct therapy.
- The present invention recognizes that the effectiveness of conventional cancer therapies such as chemotherapy, surgery and radiation can be enhanced through the use of a therapeutic material which interacts with galectins.
- While galectins are known to bind galactose and other such simple sugars in vitro, those simple sugars are not therapeutically effective in moderating galectin mediated cellular processes in vivo. While not wishing to be bound by speculation, the inventors hereof presume that relatively small sugar molecules are incapable of sustainably blocking, activating, suppressing, or otherwise interacting with other portions of the galectin protein. Therefore, preferred materials for the practice of the present invention generally comprise molecules which contain an active galectin binding sugar site, but which have somewhat higher molecular weights than simple sugars. Such molecules preferably have a minimum molecular weight of at least 300 daltons, and most typically a minimum molecular weight in the range of 300-2,000 daltons. Some specifically preferred materials have yet higher molecular weight ranges. A preferred class of therapeutic materials comprises oligomeric or polymeric species having one or more sugars such as galactose or arabinose pendent therefrom. The oligomeric or polymeric backbone may be synthetic or organic. Materials of this type are disclosed in U.S. Pat. No. ______ (EX Ser. No. 09/750,726) the disclosure of which is incorporated herein by reference. Such materials will preferably have a molecular weight in the range of 300-50,000 daltons and one particular material comprises a cellulose backbone with galactose terminated side chains pendent therefrom. It should be kept in mind that there is some inherent uncertainty in molecular weight measurements of high molecular weight carbohydrates, and measured molecular weights will be somewhat dependent on the method used for measuring the molecular weight. Molecular weights given herein are based on viscosity measurements, and such techniques are known in the art.
- One group of materials falling within this general class comprises a substantially demethoxylated polygalacturonic acid backbone having rhamnose residues pendent therefrom. It is believed that in materials of this type, the terminal galactose or arabinose units pendent from the backbone bind to galectin proteins. The remaining bulk of the molecule potentiates the compound's action in moderating immune system response; and as discussed hereinabove, the inventors, while not wishing to be bound by speculation, believe that the remaining bulk of the molecule either interacts with remaining portions of the galectin protein and/or prolongs the binding of the sugar portion thereto. Materials of this general type are described by formulas I, II and III hereinbelow, and it is to be understood that yet other variants of this general compound may be prepared and utilized in accord with th e principles of the present invention.
- where n≧1.
- Pectin is a complex carbohydrate having a highly branched structure comprised of a polygalacturonic backbone with numerous branching side chains dependent therefrom. The branching creates regions which are characterized as being “smooth” and “hairy.” It has been found that pectin can be modified by various chemical, enzymatic or physical treatments to break the molecule into smaller portions having a more linearized, substantially demethoxylated polygalacturonic backbone with pendent side chains of rhamnose residues having decreased branching. This material is known in the art as modified pectin, and its efficacy in treating cancer has been established; although galectin blocker materials of this type have not been used in conjunction with surgery, chemotherapy or radiation.
- U.S. Pat. No. 5,895,784, the disclosure of which is incorporated herein by reference, describes modified pectin materials, techniques for their preparation, and use of the material as a treatment for various cancers. The material of the '784 patent is described as being prepared by a pH based modification procedure in which the pectin is put into solution and exposed to a series of programmed changes in pH which results in the breakdown of the molecule to yield therapeutically effective modified pectin. The material in the '784 patent is most preferably prepared from citrus pectin; although, it is to be understood that modified pectins may be prepared from pectin starting material obtained from other sources, such as apple pectin and the like. Also, modification processes may be accomplished by enzymatic treatment of the pectin, or by physical processes such as heating. Further disclosure of modified pectins and techniques for their preparation and use are also disclosed in U.S. Pat. No. 5,834,442 and U.S. patent application Ser. No. 08/024,487, the disclosures of which are incorporated herein by reference. Modified pectins of this type generally have molecular weights in the range of 1-50 kilodalton, and a preferred group of such materials has an average molecular weight in the range of 1-15 kilodalton, with a specific group of materials having a molecular weight of about 10 kilodalton.
- As disclosed in the prior art, such modified pectin materials have therapeutic efficacy against a variety of cancers. These materials interact with galectins, including galectin-1 and galectin-3, and in that regard also have efficacy against immune based diseases. In accord with the present invention, the effect of conventional cancer therapies is enhanced by use of pectin materials and other materials which interact with galectins. These materials may be administered orally; or by intravenous injection; or by injection directly into an affected tissue, as for example by injection into a tumor site. In some instances the materials may be applied topically at the time surgery is carried out. Also, other techniques such as transdermal delivery systems, inhalation, subcutaneous implantation, or the like may be employed.
- Radiation therapy for cancer, which includes gamma radiation as well as particle beams, and oncolytic chemotherapeutic agents are cytotoxic, and their effectiveness in treating cancer is based upon the fact that cancerous cells are generally more sensitive to such cytotoxic therapies than are normal cells either because of their rapid metabolism, or because they employ biochemical pathways not employed by normal cells. It is believed that these therapies exert their cytotoxic effects by activating programmed cell death, also referred to as apoptosis. Cells undergo apoptosis when they undergo a critical level of damage. A balance between the activities of apoptotic and anti-apoptotic intracellular signal transduction pathways is important toward a cell's decision of whether to undergo apoptosis or to attempt internal repair. It has been demonstrated that galectins, and specifically galectin-3, are involved in both apoptosis resistance and tumor progression.
- Galectin-3 has been implicated in inhibiting apoptosis in cells treated with oncolytic agents such as cisplatin, genistein and the like. It was found that genistein effectively induces apoptosis, without detectable cell cycle arrest, in BT549 cells, which comprise a human breast epithelial cell line that does not express detectable levels of galectin-3. However, when galectin-3 transfected BT549 cells are treated with genistein, cell cycle arrest at the G(2)/M phase takes place without apoptosis induction (Lin et al. Galectin-3 mediates genistein-induced G(2)/M arrest and inhibits apoptosis. Carcinogenesis 2000 November; 21(11):1941-5). It was also found that although BT549 cells undergo anoikis, galectin-3 overexpressing BT549 cells respond to the loss of cell adhesion induced by G1 arrest without detectable cell death. Studies also suggest that galectin-3 is a critical determinant for anchorage-independent cell survival of disseminating cancer cells in the circulation during metastasis. (Kim et al. Cell cycle arrest and inhibition of anoikis by galectin-3 in human breast epithelial cells.Cancer Res. 1999 Aug. 15; 59(16):4148-54).
- Galectin-3 has also been shown to protect cells from apoptosis by moderating cell-cell and cell-matrix interaction, and has been shown to be involved in tumor progression and metastasis. When galectin-3 transfected human breast cancer cells are compared with their parent cell line which do not express galectin-3, it is found that the overexpressing cells: (1) had a significantly enhanced adhesion to laminin, fibronectin and vitronectin exerted both directly and/or via increased expression of specific integrins; the cells also exhibited (2) a remodeling of those cytoskeletal elements associated with cell spreading, i.e. microfilaments; and (3) enhanced survival upon exposure to different apoptotic stimuli such as cytokine and radiation (Matarrese et al. Galectin-3 overexpression protects from apoptosis by improving cell adhesion properties.Int. J Cancer 2000 Feb. 15; 85(4):545-54).
- The role of galectins in promoting angiogenesis has also been shown. It is known that in order for a primary tumor to grow or metastasize the cell must release chemical information instructing endothelial cells to form blood vessels which nourish and support the tumor cell. Galectins have also proven to be involved in the processes of metastasis and angiogenesis. It is shown that galectin-3 affects chemotaxis and morphology, and stimulates capillary tube formation of IIUV-EC-C in vitro and angiogenesis in vivo. Endothelial cell morphogenesis is a carbohydrate-dependent process which is neutralized by specific sugars and antibodies. These findings demonstrate that endothelial cell surface carbohydrate recognition events can induce a signaling cascade leading to the differentiation and angiogenesis of endothelial cells (Nangia-Makker et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis.Am. J. Pathol. 2000 March; 156(3):899-909). The materials of the present invention have been demonstrated to interact with galectins and inhibit angiogenesis.
- Clearly, galectins in general and galectin-3 in particular have been demonstrated to have diverse and very significant effects on the growth and proliferation of cancer cells. Furthermore, compounds which block or neutralize the activity of galectins inhibit angiogenesis and promote apoptosis. Therefore, such material will beneficially enhance the effects of oncolytic therapies. Also, it has been demonstrated that such materials will strongly inhibit angiogenesis and/or metastasis; therefore, these materials will prevent or minimize metastatic events induced by surgical disruption of a tumor site.
- In accord with the present invention, a galectin binding therapeutic material is administered to a patient, in combination with conventional therapies such as surgery, radiation or chemotherapy. The material is most preferably administered prior to the administration of the conventional therapy, so as to allow it sufficient time to interact with and bind to galectins in the tumor or in non-cancerous cells. Depending on the nature of the cancer and the therapy, administration of the galectin binding therapeutic material may be continued while the other therapy is being administered and/or thereafter. Administration of the galectin binding material may be made in a single dose, or in multiple doses. In some instances, administration of the therapeutic material is commenced at least several days prior to the conventional therapy, while in other instances, administration is begun either immediately before or at the time of the administration of the conventional therapy. In some instances, particularly with regard to surgical therapies, the carbohydrate material may be advantageously administered both before, during and after the therapy.
- The foregoing discussion has been primary directed toward modified pectin materials and materials which interact with galectins-1 and 3; however, it is to be understood that other galectins are also known to be involved in the progress of various cancers, and both the modified pectin material as well as the other therapeutic materials discussed hereinabove interact with galectins. Therefore, other materials and methods may be employed in the practice of the present invention. The foregoing discussion and description is illustrative of specific embodiments, but is not meant to be a limitation upon the practice thereof. It is the following claims, including all equivalents, which define the scope of the invention.
Claims (22)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/657,383 US20040043962A1 (en) | 2001-06-21 | 2003-09-08 | Method for enhancing the effectiveness of cancer therapies |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29999101P | 2001-06-21 | 2001-06-21 | |
US10/176,235 US6680306B2 (en) | 2001-06-21 | 2002-06-20 | Method for enhancing the effectiveness of cancer therapies |
US10/657,383 US20040043962A1 (en) | 2001-06-21 | 2003-09-08 | Method for enhancing the effectiveness of cancer therapies |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/176,235 Continuation US6680306B2 (en) | 2001-06-21 | 2002-06-20 | Method for enhancing the effectiveness of cancer therapies |
Publications (1)
Publication Number | Publication Date |
---|---|
US20040043962A1 true US20040043962A1 (en) | 2004-03-04 |
Family
ID=26872020
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/176,235 Expired - Fee Related US6680306B2 (en) | 2001-06-21 | 2002-06-20 | Method for enhancing the effectiveness of cancer therapies |
US10/408,723 Abandoned US20040023925A1 (en) | 2001-06-21 | 2003-04-07 | Method for enhancing the effectiveness of therapies of hyperproliferative diseases |
US10/657,383 Abandoned US20040043962A1 (en) | 2001-06-21 | 2003-09-08 | Method for enhancing the effectiveness of cancer therapies |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/176,235 Expired - Fee Related US6680306B2 (en) | 2001-06-21 | 2002-06-20 | Method for enhancing the effectiveness of cancer therapies |
US10/408,723 Abandoned US20040023925A1 (en) | 2001-06-21 | 2003-04-07 | Method for enhancing the effectiveness of therapies of hyperproliferative diseases |
Country Status (11)
Country | Link |
---|---|
US (3) | US6680306B2 (en) |
EP (1) | EP1406639A4 (en) |
JP (1) | JP2004535430A (en) |
CN (1) | CN100558367C (en) |
AU (1) | AU2002320140B2 (en) |
BR (1) | BR0210550A (en) |
CA (1) | CA2451841A1 (en) |
CZ (1) | CZ200487A3 (en) |
IL (1) | IL159461A0 (en) |
MX (1) | MXPA03012021A (en) |
WO (1) | WO2003000118A2 (en) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
US8871925B2 (en) | 2011-12-28 | 2014-10-28 | Galectin Therapeutics Inc. | Compositions of novel carbohydrate drug for treatment of human diseases |
US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
US9872909B2 (en) | 2012-09-17 | 2018-01-23 | Galeotin Therapeutics, Inc. | Method for enhancing specific immunotherapies in cancer treatment |
Families Citing this family (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0207961B8 (en) * | 2001-03-14 | 2021-05-25 | Bristol Myers Squibb Co | use of epothilone and capecitabine analogues to manufacture medicine to treat solid cancerous tumors and kit comprising said compounds. |
US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
US20030004132A1 (en) * | 2001-06-22 | 2003-01-02 | Yan Chang | Method and material for treating immune diseases |
US6890906B2 (en) | 2001-11-21 | 2005-05-10 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
US20040121981A1 (en) * | 2001-11-21 | 2004-06-24 | Glycogenesys, Inc. | Method for controlling angiogenesis in animals |
US20040259816A1 (en) * | 2002-10-01 | 2004-12-23 | Pandol Stephen J. | Compositions comprising plant-derived polyphenolic compounds and inhibitors of reactive oxygen species and methods of using thereof |
JP2006522163A (en) * | 2003-04-07 | 2006-09-28 | グリコジェネシス, インク. | Compositions and uses of galectin antagonists |
US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
WO2005007110A2 (en) * | 2003-07-11 | 2005-01-27 | Pro-Pharmaceuticals, Inc. | Compositions and methods for hydrophobic drug delivery |
DE10335236B3 (en) * | 2003-08-01 | 2005-02-24 | Drägerwerk AG | Measuring system for the determination of the concentration of propofol (2,6-diisopropylphenol) in the respiratory flow |
US20050053664A1 (en) * | 2003-09-08 | 2005-03-10 | Eliezer Zomer | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
EP1682159A4 (en) * | 2003-10-16 | 2010-07-21 | Stephen John Ralph | Immunomodulating compositions and uses therefor |
US20050282773A1 (en) * | 2004-01-14 | 2005-12-22 | Pro-Pharmaceuticals, Inc. | Modified polysaccharides in combination with anti-cancer drugs for enhanced treatment of cancer |
US20070078109A1 (en) * | 2004-02-13 | 2007-04-05 | David Platt | Compositions and methods used to treat acne and candida |
CA2582428A1 (en) | 2004-03-26 | 2005-10-13 | Glycogenesys, Inc. | Modified pectins, compositions and methods related thereto |
WO2006020027A1 (en) * | 2004-07-14 | 2006-02-23 | Glycogenesys, Inc. | Composition and method for treating hyperproliferative diseases |
US20080286251A1 (en) * | 2004-08-02 | 2008-11-20 | Propharmaceuticals, Inc. | Compositions and Methods for the Enhancement of Chemotherapy with Microbial Cytotoxins |
US20090074787A1 (en) * | 2005-03-23 | 2009-03-19 | Pfizer, Inc., Pfizer Products, Inc. | Anti-CTLA4 Antibody and Indolinone Combination Therapy for Treatment of Cancer |
US8221803B1 (en) | 2007-06-25 | 2012-07-17 | OncoNatural Solutions, Inc. | Composition for prostate health |
EP2184997A4 (en) * | 2007-07-31 | 2010-11-03 | Univ New York | Diagnostic and treatment methods for characterizing bacterial microbiota in skin conditions |
WO2011060272A2 (en) | 2009-11-13 | 2011-05-19 | Dana-Farber Cancer Institute, Inc. | Compositions, kits, and methods for the diagnosis, prognosis, monitoring, treatment and modulation of post-transplant lymphoproliferative disorders and hypoxia associated angiogenesis disorders using galectin-1 |
AU2012348311B2 (en) * | 2011-12-08 | 2014-06-12 | Eliaz Therapeutics, Inc. | Reduction of galectin-3 levels by plasmapheresis |
WO2013152313A1 (en) * | 2012-04-05 | 2013-10-10 | The Regents Of The University Of California | Compositions and methods for treating cancer and diseases and conditions responsive to growth factor inhibition |
WO2015071910A1 (en) | 2013-11-17 | 2015-05-21 | Rdd Pharma Ltd. | Methods for treating radiation induced gastrointestinal tract injury |
EP3512560A4 (en) * | 2016-09-13 | 2020-05-27 | Rasna Research Inc. | Dactinomycin compositions and methods for the treatment of myelodysplastic syndrome and acute myeloid leukemia |
MX2019013537A (en) | 2017-05-12 | 2020-02-13 | Galectin Sciences Llc | Compounds for the prevention and treatment of diseases and the use thereof. |
US11633399B2 (en) | 2018-12-25 | 2023-04-25 | Sol-Gel Technologies Ltd. | Treatment of skin disorders with compositions comprising an EGFR inhibitor |
Citations (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
US5639737A (en) * | 1991-11-04 | 1997-06-17 | Co Enzyme Technology Ltd. | Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors |
US5681923A (en) * | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
US5843442A (en) * | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
US6274566B1 (en) * | 1999-02-23 | 2001-08-14 | Econugenics, Inc. | Methods for treating mammals with modified alginates and pectins |
US20020104222A1 (en) * | 2001-02-06 | 2002-08-08 | Jay Larry Dean | Knife for removing the hide of an animal and method therefor |
US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
US20030013681A1 (en) * | 2001-06-21 | 2003-01-16 | Yan Chang | Method for enhancing the effectiveness of cancer therapies |
US20030064957A1 (en) * | 2001-03-27 | 2003-04-03 | Anatole Klyosov | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
US6642205B2 (en) * | 2000-09-25 | 2003-11-04 | Pro-Pharmaceuticals, Inc. | Methods and compositions for reducing side effects in chemotherapeutic treatments |
US6645946B1 (en) * | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
US6875451B2 (en) * | 1997-10-15 | 2005-04-05 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
US6914055B2 (en) * | 2001-03-27 | 2005-07-05 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
US6982255B2 (en) * | 2001-03-27 | 2006-01-03 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US107222A (en) * | 1870-09-13 | Improvement in machines for tenoning window-sash | ||
US20020107222A1 (en) | 1993-03-01 | 2002-08-08 | David Platt | Modified polysaccharides for treatment of cancer |
US5490911A (en) * | 1993-11-26 | 1996-02-13 | The United States Of America As Represented By The Department Of Energy | Reactive multilayer synthesis of hard ceramic foils and films |
AU1735097A (en) * | 1996-03-15 | 1997-10-01 | Takara Shuzo Co., Ltd. | A product of heat treatment of uronic acid, food, drink or drug including the product |
US20040223971A1 (en) * | 2003-04-07 | 2004-11-11 | Glycogenesys, Inc. | Composition and uses of galectin antagonists |
WO2006020027A1 (en) * | 2004-07-14 | 2006-02-23 | Glycogenesys, Inc. | Composition and method for treating hyperproliferative diseases |
-
2002
- 2002-06-20 US US10/176,235 patent/US6680306B2/en not_active Expired - Fee Related
- 2002-06-21 BR BR0210550-0A patent/BR0210550A/en not_active IP Right Cessation
- 2002-06-21 EP EP02749641A patent/EP1406639A4/en not_active Withdrawn
- 2002-06-21 CA CA002451841A patent/CA2451841A1/en not_active Abandoned
- 2002-06-21 IL IL15946102A patent/IL159461A0/en unknown
- 2002-06-21 CN CNB028160037A patent/CN100558367C/en not_active Expired - Fee Related
- 2002-06-21 MX MXPA03012021A patent/MXPA03012021A/en not_active Application Discontinuation
- 2002-06-21 JP JP2003506572A patent/JP2004535430A/en active Pending
- 2002-06-21 CZ CZ200487A patent/CZ200487A3/en unknown
- 2002-06-21 AU AU2002320140A patent/AU2002320140B2/en not_active Ceased
- 2002-06-21 WO PCT/US2002/019885 patent/WO2003000118A2/en active Application Filing
-
2003
- 2003-04-07 US US10/408,723 patent/US20040023925A1/en not_active Abandoned
- 2003-09-08 US US10/657,383 patent/US20040043962A1/en not_active Abandoned
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5490991A (en) * | 1986-07-03 | 1996-02-13 | Advanced Magnetics, Inc. | Directed delivery of radioprotectants using a receptor specific carrier |
US5843442A (en) * | 1990-10-22 | 1998-12-01 | Corvas International, Inc. | Blood coagulation protein antagonists and uses therefor |
US5639737A (en) * | 1991-11-04 | 1997-06-17 | Co Enzyme Technology Ltd. | Method and compositions for treating malignant tumors and inhibiting growth and metastases of malignant tumors |
US5498702A (en) * | 1993-12-16 | 1996-03-12 | California Natural Products | Treated pectinic acid process and product |
US5895784A (en) * | 1994-07-07 | 1999-04-20 | Michigan Cancer Foundation | Method for treatment of cancer by oral administration of modified pectin |
US5834442A (en) * | 1994-07-07 | 1998-11-10 | Barbara Ann Karmanos Cancer Institute | Method for inhibiting cancer metastasis by oral administration of soluble modified citrus pectin |
US6423314B2 (en) * | 1995-10-06 | 2002-07-23 | David Platt | Tumor derived carbohydrate binding protein |
US5681923A (en) * | 1995-10-06 | 1997-10-28 | Platt; David | Tumor derived carbohydrate binding protein |
US5831052A (en) * | 1997-05-07 | 1998-11-03 | Incyte Pharmaceuticals, Inc. | New human translocation associated protein |
US6875451B2 (en) * | 1997-10-15 | 2005-04-05 | Polarx Biopharmaceuticals Inc. | Compositions and methods for the treatment of primary and metastatic neoplastic diseases using arsenic compounds |
US6258383B1 (en) * | 1998-08-14 | 2001-07-10 | Lactoferrin Products Company | Dietary supplement combining colostrum and lactoferrin in a mucosal delivery format |
US6500807B1 (en) * | 1999-02-02 | 2002-12-31 | Safescience, Inc. | Modified pectin and nucleic acid composition |
US6274566B1 (en) * | 1999-02-23 | 2001-08-14 | Econugenics, Inc. | Methods for treating mammals with modified alginates and pectins |
US6642205B2 (en) * | 2000-09-25 | 2003-11-04 | Pro-Pharmaceuticals, Inc. | Methods and compositions for reducing side effects in chemotherapeutic treatments |
US20020104222A1 (en) * | 2001-02-06 | 2002-08-08 | Jay Larry Dean | Knife for removing the hide of an animal and method therefor |
US6645946B1 (en) * | 2001-03-27 | 2003-11-11 | Pro-Pharmaceuticals, Inc. | Delivery of a therapeutic agent in a formulation for reduced toxicity |
US20030064957A1 (en) * | 2001-03-27 | 2003-04-03 | Anatole Klyosov | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
US6914055B2 (en) * | 2001-03-27 | 2005-07-05 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
US6982255B2 (en) * | 2001-03-27 | 2006-01-03 | Anatole Klyosov | Delivery of a therapeutic agent in a formulation for reduced toxicity |
US7012068B2 (en) * | 2001-03-27 | 2006-03-14 | Pro-Pharmaceuticals, Inc. | Co-administration of a polysaccharide with a chemotherapeutic agent for the treatment of cancer |
US6680306B2 (en) * | 2001-06-21 | 2004-01-20 | Glycogenesys, Inc. | Method for enhancing the effectiveness of cancer therapies |
US20030013681A1 (en) * | 2001-06-21 | 2003-01-16 | Yan Chang | Method for enhancing the effectiveness of cancer therapies |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8871925B2 (en) | 2011-12-28 | 2014-10-28 | Galectin Therapeutics Inc. | Compositions of novel carbohydrate drug for treatment of human diseases |
US8962824B2 (en) | 2011-12-28 | 2015-02-24 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US9649327B2 (en) | 2011-12-28 | 2017-05-16 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US9974802B2 (en) | 2011-12-28 | 2018-05-22 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US10420793B2 (en) | 2011-12-28 | 2019-09-24 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US10799525B2 (en) | 2011-12-28 | 2020-10-13 | Galectin Therapeutics, Inc. | Composition of novel carbohydrate drug for treatment of human diseases |
US11413303B2 (en) | 2011-12-28 | 2022-08-16 | Galectin Therapeutics, Inc. | Methods for treatment of arthritis |
US9763974B2 (en) | 2012-06-06 | 2017-09-19 | Galectin Therapeutics, Inc. | Galacto-rhamnogalacturonate compositions for the treatment of diseases associated with elevated inducible nitric oxide synthase |
US9872909B2 (en) | 2012-09-17 | 2018-01-23 | Galeotin Therapeutics, Inc. | Method for enhancing specific immunotherapies in cancer treatment |
US10398778B2 (en) | 2012-09-17 | 2019-09-03 | Galectin Therapeutics, Inc. | Method for enhancing specific immunotherapies in cancer treatment |
US8828971B2 (en) | 2012-10-10 | 2014-09-09 | Galectin Therapeutics, Inc. | Galactose-pronged carbohydrate compounds for the treatment of diabetic nephropathy and associated disorders |
US9339515B2 (en) | 2013-02-20 | 2016-05-17 | Galectin Therapeutics, Inc. | Method for treatment of pulmonary fibrosis |
Also Published As
Publication number | Publication date |
---|---|
US6680306B2 (en) | 2004-01-20 |
CA2451841A1 (en) | 2003-01-03 |
WO2003000118A3 (en) | 2003-04-10 |
AU2002320140B2 (en) | 2007-11-29 |
CZ200487A3 (en) | 2004-10-13 |
EP1406639A4 (en) | 2004-07-28 |
US20030013681A1 (en) | 2003-01-16 |
EP1406639A2 (en) | 2004-04-14 |
JP2004535430A (en) | 2004-11-25 |
WO2003000118A2 (en) | 2003-01-03 |
BR0210550A (en) | 2004-05-25 |
IL159461A0 (en) | 2004-06-01 |
US20040023925A1 (en) | 2004-02-05 |
MXPA03012021A (en) | 2004-06-03 |
CN1543351A (en) | 2004-11-03 |
CN100558367C (en) | 2009-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6680306B2 (en) | Method for enhancing the effectiveness of cancer therapies | |
AU2002320140A1 (en) | Method for enhancing the effectiveness of cancer therapies | |
Nagaraja et al. | Role of human and mouse HspB1 in metastasis | |
KR20230065977A (en) | Interferon-Based Methods and Pharmaceutical Combinations for Cancer Treatment | |
Gaudin et al. | The effect of DNA repair inhibitors on the response of tumors treated with X-ray and alkylating agents | |
CN112972688A (en) | Application of PPAR delta inhibitor and immunotherapy drug in preparation of antitumor drugs | |
JP2010529049A (en) | Use of naringenin and naringin as transforming growth factor-β1 signaling pathway inhibitors | |
Park et al. | Antiangiogenic effect of bile acid acylated heparin derivative | |
CN108186643B (en) | Pharmaceutical composition with synergistic osteosarcoma resistance effect and application thereof | |
JP2011506467A (en) | Method of treatment of melanoma with alpha thymosin peptide combined with antineoplastic heat shock apoptosis activator (HSAA) | |
EP2732044B1 (en) | Novel zinc finger-like peptide compositions as potent agents in cancer prevention and treatment | |
CN116059374A (en) | Application of LCAT gene and purified protein in preparation of medicine for preventing, relieving and/or treating primary hepatocellular carcinoma | |
WO2009033047A2 (en) | Methods and compositions for treating diseases and conditions involving higher molecular weight hyaluronan | |
EP4115902A1 (en) | Combined use of ctb006 and ponatinib | |
WO2000056334A1 (en) | Use of imino sugars for anti-tumor therapy | |
Jakobsson et al. | Protamine and mast-cell-mediated angiogenesis in the rat. | |
Amagase et al. | Epidermal growth factor receptor‐mediated selective cytotoxicity of antitumor agents toward human xenografts and murine syngeneic solid tumors | |
KR20100107461A (en) | Pharmaceutical composition and combined agent | |
Gonzalez et al. | Radiotoxicity of h-R3 monoclonal antibody labeled with 188Re administered intracerebrally in rats | |
Zheng et al. | Synergistic anti-tumor effect of recombinant chicken fibroblast growth factor receptor-1-mediated anti-angiogenesis and low-dose gemcitabine in a mouse colon adenocarcinoma model | |
WO2005072292A2 (en) | Methods for enhancing radiation therapy | |
CN110876803B (en) | Pharmaceutical composition containing milk protein and oleic acid | |
KR102212699B1 (en) | Composition for the prevention or treatment of breast cancer | |
Uhlenbruck et al. | Prevention of experimental liver metastases by D-galactose | |
WO2015184248A1 (en) | Methods of treating fibrotic diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: GLYCOGENESYS, INC., MASSACHUSETTS Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHANG, YAN;SASAK, VODEK;REEL/FRAME:016652/0688 Effective date: 20020617 |
|
AS | Assignment |
Owner name: MARLBOROUGH RESEARCH AND DEVELOPMENT INC., MASSACH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DEGIACOMO, MARK G., CHAPTER 7 TRUSTEE, GLYCOGENESYS, INC.;REEL/FRAME:018777/0643 Effective date: 20061122 |
|
AS | Assignment |
Owner name: MARLBOROUGH RESEARCH AND DEVELOPMENT INC., MASSACH Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:DEGIACOMO, MARK G., CHAPTER 7 TRUSTEE GLYCOGENESYS, INC.;REEL/FRAME:018917/0380 Effective date: 20061122 Owner name: PROSPECT PHARMACEUTICALS, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:MARLBOROUGH RESEARCH AND DEVELOPMENT, INC.;REEL/FRAME:018917/0374 Effective date: 20070116 Owner name: PROSPECT THERAPEUTICS, INC., MASSACHUSETTS Free format text: CHANGE OF NAME;ASSIGNOR:PROSPECT PHARMACEUTICALS, INC.;REEL/FRAME:018917/0395 Effective date: 20070130 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |